September Monthly Roundup: 5 Focus Areas as Portfolio Keeps Its YTD Lead
We raised cash early, put some back to work late in the month, locked in gains on Meta and kicked off our quarterly EPS All-Stars reconstitution.
Small Biotech Name Hits Radar With Promising Hair Loss Play
As higher interest rates drive two-tiered market action, I’m watching this name.
Interest Rates Created a Two-Tiered Market. Earnings Will Test It.
Oversold conditions and positive seasonality look promising, but we still need price action to confirm a turn.
How to Trade This Cash-Rich Biopharma Name
This weekend’s covered call idea is around a cash-rich biopharma concern that is expecting a key FDA approval to close out 2026.
Bearish Bets: 3 Stocks to Short on Textbook Downtrends
Here’s how we’d play these names with bearish charts.
Trade Like a Young Warren Buffett, Not Like Berkshire
As a trader, Buffett could spot gaps between price and value that the market was missing. And then his billions got in the way.
Another Overhang Removed for Boeing
FAA says Boeing 737 Max software glitch is not a flight-safety issue.
Downgrading a Holding That’s Increasingly Hard to Defend
We’re laying out our revised game plan for this laggard.
Cathie Wood’s Firm Makes $16 Million Rocket Lab Decision
We sold some of our position in the aerospace firm alongside ARK Invest.